Pfizer (NYSE:PFE) is one of those names where the headline narrative (COVID hangover, patent cliff) keeps overshadowing what ...

With a market cap of $149.2 billion, Pfizer Inc. (PFE) is a global biopharmaceutical company that discovers, develops, ...

Pfizer (NYSE: PFE) recently experienced yet another setback. The drugmaker has been posting disappointing financial results for several years, and its latest quarterly update sent its stock price down ...

As with other pharma companies, much rides on Pfizer's pipeline; it has many promising formulations in late-stage trials.

Pfizer is an over-100-year-old drug company going through a rough patch, which has happened before.

Whichever one you choose, you'll need patience before you can see solid returns.

Pfizer (PFE +0.19%) stock reached all-time highs earlier this decade thanks to the company's dominance in the market for coronavirus vaccines and medicines. However, the pharmaceu ...

I last covered Pfizer Inc. stock (NYSE:PFE) on Feb 19. The article rated the stock as hold after examining its FQ4 earnings report (ER) and dividend declarations. Since then, a few new catalysts have ...

Coverage on Pfizer is broad and divided, leaning toward cautious optimism. On average, analysts recommend holding shares, and they have a $29.19 consensus price target. Recent actions paint the same ...